Skip to main content
Caplight Logo









Immuneel Therapeutics

Immuneel Therapeutics

Private
BangaloreHealthcare & Life Scienceshttps://immuneel.com/

Last Round

Series B

Jun 8, 2026

Est. Valuation

$71M

Total Funding Raised

$52.65M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Immuneel Therapeutics is a biotechnology company that develops affordable cell and gene therapies, including CAR-T therapies, for the treatment of cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine, Lending & Credit

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

CAR-T cell therapycell and gene therapyimmunotherapycancer treatmentblood cancerchimeric antigen receptorpatient financingzero-cost EMImedical financingbiopharmaclinical-stage biotechliving drugspersonalized medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Immuneel Therapeutics Comparables

Compare Immuneel Therapeutics with similar companies based on industry and business-model similarity.

Immuneel Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ImmunoACT
89%
Cellogen Therapeutics
85%
AbelZeta Pharma
78%

Immuneel Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJun 8, 2026
GrantJun 10, 2025
Series A ExtensionJul 10, 2024
Series AJun 21, 2022
SeedJan 8, 2020

Key People

Founding team and executive leadership

CA Gaurav Nanda

Chief Financial Officer

Executive Team

Immuneel Therapeutics Investors

Notable investors and investment history

Immuneel Therapeutics investors
InvestorRounds
Rainmatter Capital FundSeries B
F-Prime CapitalSeries A, Seed
Eight Roads VenturesSeries B, Series A, Seed
Singularity AMCSeries B
F-Prime CapitalSeries B, Series A
True NorthSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors grew 311% MoM, reaching 14.2K.

  • Jan 8, 2026

    Partnered with healthcare lending marketplace CarePal Money.

Recent news

Latest coverage and updates

  • partners_withJul 27, 2026

    Immuneel partnered with Thsti on Jul 27th '26.

  • partners_withJul 20, 2026

    Immuneel Therapeutics Private Limited partnered with Tata Memorial Centre on Jul 1st '26.

  • launchesJul 6, 2026

    Immuneel Therapeutics Private Limited launched zero-cost EMI programme on Jul 6th '26.

  • partners_withJul 6, 2026

    Immuneel Therapeutics Private Limited partnered with Arogya Finance on Jul 6th '26.

Immuneel Therapeutics Filings

Explore SEC and related filing metadata, where available.

Immuneel Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Immuneel Therapeutics's valuation, stock price, and market status.

Is Immuneel a public or private company?

Immuneel is a private company.

What is the current stock price of Immuneel?

Immuneel is a private company with no public stock price. No recent secondary market data is available.

How much is Immuneel worth (valuation)?

Immuneel's valuation is estimated at $71.0M based on funding round data.

Can I buy Immuneel stock?

Immuneel shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Immuneel's last funding round?

Immuneel's most recent funding round was Grant on July 9, 2024.

Who are the main investors in Immuneel?

Key investors in Immuneel include F-Prime Capital, Eight Roads Ventures, True North.

Will Immuneel IPO soon?

No public IPO plans have been announced for Immuneel.

How can I track Immuneel secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Immuneel's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBangalore
Employee Range100
Year Founded2018
Last FundingJun 8, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?